Highlights Qiagen N.V.

Equities

QGEN

NL0015002CX3

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2025-12-04 pm EST			5-day change	1st Jan Change
47.08 ^USD	+0.56%		-2.12%	+2.79%

Dec. 03	Qiagen N.V. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10:50 AM
Dec. 02	Qiagen N.V. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 11:15 AM

Highlights

Rebounds expected in Europe, focus on US reports	Nov. 20	AN
Cellbxhealth, Qiagen Unit Enter Co-marketing Deal	Nov. 18	MT
Qiagen Seeks Acquisitions	Nov. 17	CI
QIAGEN N.V. Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025	Nov. 10	CI
Qiagen lifts adjusted EPS guidance after Q3 earnings beat and Parse Biosciences acquisition	Nov. 05
Qiagen N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	Nov. 04	CI
Qiagen N.V. Reaffirms Earnings Guidance for the Fiscal Year 2025	Nov. 04	CI
(QGEN) QIAGEN Expects Q4 Adjusted EPS $0.60, vs. FactSet Est of $0.61	Nov. 04	MT
Qiagen to Acquire Parse Biosciences for Up to $280 Million to Expand Single-Cell Portfolio	Nov. 04	MT
(QGEN) QIAGEN Revises Full Year 2025 Adjusted EPS Outlook To About $2.38, vs. FactSet Est of $2.34	Nov. 04	MT
Earnings Flash (QGEN) QIAGEN Posts Q3 Revenue $533M, vs. FactSet Est of $525.9M	Nov. 04	MT
Qiagen Q3 Adjusted Earnings, Revenue Rise; 2025 Adjusted EPS Guidance Boosted	Nov. 04	MT
Earnings Flash (QGEN) QIAGEN Posts Q3 Adjusted EPS $0.61, vs. FactSet Est of $0.59	Nov. 04	MT
Qiagen says Thierry Bernard to step down as chief executive officer	Nov. 04	RE
Qiagen NV raises FY adjusted EPS target to about $2.38 CER	Nov. 04	RE
Qiagen to acquire Parse Biosciences	Nov. 04	RE
Qiagen to return about $500 million to shareholders through synthetic share repurchase	Nov. 04	RE
Qiagen N.V. entered into a definitive agreement to acquire Parse Biosciences, Inc. for $280 million.	Nov. 03	CI
QIAGEN N.V. Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025	Oct. 30	CI
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing	Oct. 28	CI
EU sees pharmaceutical exports protected from 100 percent US tariffs	Sep. 26	DP
Medical Technology Sector Under Pressure - US Tariff Probe Casts a Shadow	Sep. 25	DP
QIAGEN N.V. Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing	Sep. 02	CI
Qiagen gains U.S. clearance of higher-throughput QIAstat-Dx Rise	Sep. 02	RE
Qiagen N.V. announces $750 million convertible bonds due 2032	Aug. 28	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Qiagen lifts adjusted EPS guidance after Q3 earnings beat and Parse Biosciences acquisition

November 05, 2025 at 09:14 am EST